Next Science Limited (NXSCF) Research

Next Science Limited operates as a medical technology firm, dedicated to the research, development, and commercialization of innovative solutions aimed at mitigating the detrimental effects of biofilms on human health. The company serves markets in both the United States and Australia, building its product portfolio on its proprietary Xbio Technology platform. Among its key offerings are: SURGX: An antimicrobial gel employed for managing surgical infections. BACTISURE: A specialized wound lavage designed to eliminate biofilm. BlastX: An antimicrobial wound gel that not only eradicates bacteria within the gel but also wards off recolonization, all while maintaining an optimal moist healing environment. XPERIENCE: A no-rinse antimicrobial solution developed specifically to deter surgical site infections. Established in 2012, Next Science Limited maintains its primary operational base in Chatswood, Australia.

Market snapshot

Symbol
NXSCF
Price
$0.00
Day change
-93.75%
Market cap
$29.8M
P/E ratio
-4.20x
52-week range
0.0002-0.1133
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Alternate Health Corp. (AHGIF)
  • Fluent Corp. (CNTMF)
  • Charlotte's Web Holdings, Inc. (CWBHF)
  • Nova Eye Medical Limited (ELXMF)
  • Ecofibre Limited (EOFBF)
  • High Sierra Technologies, Inc. (HSTI)
  • iAnthus Capital Holdings, Inc. (ITHUF)
  • MediPharm Labs Corp. (MEDIF)

Open Next Science Limited (NXSCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.